Oncotelic Therapeutics, Inc.
OTLC
$0.04
$0.001.27%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 249.28M | -1.67M | -3.93M | -4.41M | -4.52M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | 198.10K | 140.60K | 100.90K | 123.00K | 122.10K |
| Total Other Non-Cash Items | -250.97M | 318.70K | 2.83M | 3.29M | 3.31M |
| Change in Net Operating Assets | 106.40K | 505.80K | 457.10K | 327.40K | 348.40K |
| Cash from Operations | -1.38M | -704.10K | -540.30K | -675.90K | -740.30K |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 1.39M | 964.00K | 556.00K | 566.00K | 656.00K |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 1.39M | 964.00K | 556.00K | 566.00K | 656.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2.70K | 259.90K | 15.70K | -109.90K | -84.30K |